Portrait of blood-derived extracellular vesicles in patients with Parkinson’s disease

• Published in: Neurobiology of disease Vol. 124; pp. 163 - 175
• Main Authors: Lamontagne-Proulx, Jérôme, St-Amour, Isabelle, Labib, Richard, Pilon, Jérémie, Denis, Hélèna L., Cloutier, Nathalie, Roux-Dalvai, Florence, Vincent, Antony T., Mason, Sarah L., Williams-Gray, Caroline, Duchez, Anne-Claire, Droit, Arnaud, Lacroix, Steve, Dupré, Nicolas, Langlois, Mélanie, Chouinard, Sylvain, Panisset, Michel, Barker, Roger A., Boilard, Eric, Cicchetti, Francesca
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2019; Elsevier
• Subjects: Aged; Alpha-synuclein; Biomarkers - blood; Blood Cell Count; Blood cells; Erythrocytes; Erythrocytes - metabolism; Erythrocytes - ultrastructure; Extracellular vesicles; Extracellular Vesicles - metabolism; Extracellular Vesicles - ultrastructure; Female; Humans; Huntington Disease - blood; Huntington Disease - diagnosis; Huntington Disease - pathology; Life Sciences; Male; Middle Aged; Parkinson Disease - blood; Parkinson Disease - diagnosis; Parkinson Disease - pathology; Proteomics; EV; PD; Blood cells; Erythrocytes; EEV; Extracellular vesicles; UPDRS; LEDD; Alpha-synuclein
• ISSN: 0969-9961; 1095-953X; 1095-953X
• DOI: 10.1016/j.nbd.2018.11.002

The production of extracellular vesicles (EV) is a ubiquitous feature of eukaryotic cells but pathological events can affect their formation and constituents. We sought to characterize the nature, profile and protein signature of EV in the plasma of Parkinson's disease (PD) patients and how they correlate to clinical measures of the disease. EV were initially collected from cohorts of PD (n = 60; Controls, n = 37) and Huntington's disease (HD) patients (Pre-manifest, n = 11; manifest, n = 52; Controls, n = 55) – for comparative purposes in individuals with another chronic neurodegenerative condition – and exhaustively analyzed using flow cytometry, electron microscopy and proteomics. We then collected 42 samples from an additional independent cohort of PD patients to confirm our initial results. Through a series of iterative steps, we optimized an approach for defining the EV signature in PD. We found that the number of EV derived specifically from erythrocytes segregated with UPDRS scores corresponding to different disease stages. Proteomic analysis further revealed that there is a specific signature of proteins that could reliably differentiate control subjects from mild and moderate PD patients. Taken together, we have developed/identified an EV blood-based assay that has the potential to be used as a biomarker for PD. •Optimization of methodology to identify extracellular vesicles (EV) using FACS.•Demonstration of minimal test-retest variability intra-individual using FACS.•Development of a new approach to uncover the entire proteome of EV.•Segregation of Parkinson's disease patients using EV from erythrocytes (EEV) count.•EEV protein signature allow to differentiate normal individuals from Parkinson's disease patients.